Healthcare innovation company Enable Injections, Inc. and biotechnology company Swedish Orphan Biovitrum AB or Sobi, announced Thursday an international development and distribution agreement for the enFuse Injector, for the subcutaneous delivery of Aspaveli (pegcetacoplan).The enFuse Injector, to be produced by Enable and distributed by Sobi, is designed to streamline and improve patients' self-administration experience with minimal disruption to their daily lives via the use of wearable enFuse technology.

周四，医疗保健创新公司Enable Injections，Inc.和生物技术公司瑞典Orphan Biovitrum AB或Sobi宣布了一项enFuse注射器的国际开发和分销协议，用于皮下注射Aspaveli（pegcetacoplan）。enFuse注射器将由Enable生产并由Sobi分发，旨在通过使用可穿戴的enFuse技术简化和改善患者的自我管理体验，同时尽量减少对其日常生活的干扰。

This allows wearable, hidden needle drug delivery through a simple injection under the skin..

这允许通过皮肤下的简单注射进行可穿戴的隐藏针头药物输送。。

Enable is currently working with a number of pharmaceutical partners to conduct clinical trials and plan for joint commercial launch of their therapies in combination with the enFuse technology. The first enFuse combination product received U.S. FDA approval in 2023. For comments and feedback contact: editorial@rttnews.comBusiness News.

Enable目前正在与许多制药合作伙伴合作进行临床试验，并计划结合enFuse技术联合商业推出其疗法。第一种enFuse组合产品于2023年获得美国FDA批准。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股